PT - JOURNAL ARTICLE AU - Michael Nakai AU - Rosilene V Ribeiro AU - Bruce R. Stevens AU - Paul Gill AU - Rikeish R. Muralitharan AU - Stephanie Yiallourou AU - Jane Muir AU - Melinda Carrington AU - Geoffrey A. Head AU - David M. Kaye AU - Francine Z. Marques TI - Essential hypertension is associated with changes in gut microbial metabolic pathways: A multi-site analysis of ambulatory blood pressure AID - 10.1101/2021.02.18.21252018 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.18.21252018 4099 - http://medrxiv.org/content/early/2021/02/22/2021.02.18.21252018.short 4100 - http://medrxiv.org/content/early/2021/02/22/2021.02.18.21252018.full AB - Aims Recent evidence supports a role for the gut microbiota in hypertension, but whether ambulatory blood pressure (BP) is associated with gut microbiota and their metabolites remains unclear. Here we characterised the function of the gut microbiota, their metabolites and receptors in untreated human hypertensive participants in metropolitan and regional areas of Australia.Methods and Results Ambulatory BP, faecal microbiome DNA 16S rRNA gene sequencing, plasma and faecal metabolites called short-chain fatty acid (SCFAs), and expression of their receptors were analysed in 70 untreated and otherwise healthy participants from metropolitan and regional communities. Based on machine-learning multivariate covariance analyses of de-noised amplicon sequence variant (ASV) prevalence data, we determined that there were no significant differences in gut microbiome community α- and β-diversity metrics between normotensives versus essential, white coat or masked hypertensives. However, select taxa were specific to these groups, notably Acidaminococcus spp. in essential hypertensives, and Ruminococcus spp. and Coprobacillus in normotensive subjects. Importantly, normotensive and essential hypertensive cohorts could be differentiated based on gut microbiome gene pathways and metabolites. Specifically, hypertensive participants exhibited higher plasma acetate and butyrate, but their immune cells expressed reduced levels of SCFA-activated G-protein coupled receptor 43 (GPR43).Conclusions While gut microbial diversity did not change in essential hypertension, there was a significant shift in microbial gene pathways, and an increase in the circulating levels of the SCFAs acetate and butyrate. Hypertensive subjects, however, had lower levels of the SCFA-sensing receptor GPR43, putatively blunting their response to BP-lowering metabolites.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is registered in the Australian New Zealand Clinical Trials Registry under ACTRN12620000958987Funding StatementThis work was supported by a National Health & Medical Research Council (NHMRC) of Australia Program Grant and fellowship to D.K, fellowship to G.A.H., and a Project Grant to F.Z.M. and D.K. F.Z.M is supported by a National Heart Foundation Future Leader Fellowship and National Heart Foundation Grants. The Baker Heart & Diabetes Institute is supported in part by the Victorian Government's Operational Infrastructure Support Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complied with the Declaration of Helsinki, and was approved by the human research ethics committee of the Alfred Hospital (ethics 415/16). All participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe microbiome data underlying this article will be made available at the GenBank Nucleotide Database (under submission at the moment). The other data underlying this article will be shared on reasonable request to the corresponding author.